AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hutter, B.
Right arrow Articles by Loferer, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hutter, B.
Right arrow Articles by Loferer, H.
Antimicrobial Agents and Chemotherapy, August 2004, p. 2838-2844, Vol. 48, No. 8
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.8.2838-2844.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Prediction of Mechanisms of Action of Antibacterial Compounds by Gene Expression Profiling

Bernd Hutter,1* Christoph Schaab,1 Sebastian Albrecht,1,{dagger} Matthias Borgmann,1 Nina A. Brunner,2 Christoph Freiberg,2 Karl Ziegelbauer,2 Charles O. Rock,3 Igor Ivanov,1 and Hannes Loferer1*

GPC Biotech AG, Munich,1 Bayer AG, Wuppertal, Germany,2 Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee 381053

Received 30 October 2003/ Returned for modification 24 January 2004/ Accepted 3 April 2004

We have generated a database of expression profiles carrying the transcriptional responses of the model organism Bacillus subtilis following treatment with 37 well-characterized antibacterial compounds of different classes. The database was used to build a predictor for the assignment of the mechanisms of action (MoAs) of antibacterial compounds by the use of support vector machines. This predictor was able to correctly classify the MoA class for most compounds tested. Furthermore, we provide evidence that the in vivo MoA of hexachlorophene does not match the MoA predicted from in vitro data, a situation frequently faced in drug discovery. A database of this kind may facilitate the prioritization of novel antibacterial entities in drug discovery programs. Potential applications and limitations are discussed.


* Corresponding author. Mailing address: GPC Biotech AG, Microbiology, Fraunhoferstr. 20, Martinsried/Munich 8152, Germany. Phone: 49 89 8565 3233. Fax: 49 89 8565 2610. E-mail for Bernd Hutter: bernd.hutter{at}gpc-biotech.com. E-mail for Hannes Loferer: hannes.loferer{at}gpc-biotech.com.

{dagger} Present address: Leogic GmbH, Munich, Germany.


Antimicrobial Agents and Chemotherapy, August 2004, p. 2838-2844, Vol. 48, No. 8
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.8.2838-2844.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2004 by the American Society for Microbiology. All rights reserved.